Feature | Heart Valve Technology | May 14, 2018

Length of Stay Impacts TAVR Outcomes

First-of-its-kind study includes independent predictors of early and delayed discharge; and shows delayed discharge associated with worse one-year outcomes

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femoral transcatheter aortic valve replacement (TF-TAVR) procedure may be associated with negative short and long-term outcomes. The authors, for the first time, report a significant decline in the rates of delayed discharge; and identified independent predictors of both delayed and early discharge post TAVR. The study was presented as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions.

More than 5 million Americans are diagnosed with heart valve disease each year.[1] TAVR is a procedure used for patients (at high or intermediate risk for surgical aortic valve replacement) with severe narrowing of the aortic vessel where a prosthetic valve is implanted and the damaged valve is replaced. While the strategy of early discharge is important from administrative and financial view point; such practice, may also come with additive clinical benefit in terms of improved short and long-term outcomes. Hence, the aim of this study was to investigate the trends, predictors, and outcomes associated with length of stay (LOS) post TF-TAVR.

Patients undergoing non-aborted transfemoral TAVR, (n=32,847) and survived to discharge (n=24,285) in the Transcatheter Valve Therapy (TVT) Registry from 2011-2015 were categorized as early discharge (ED<72 hours) or delayed discharge (DD). During the study period, there was a significant decline in the rates of DD (62.2 percent in 2012 Q1 versus 34.4 percent 2015 Q3). The study for the first time delineates distinct independent predictors of early/late discharge (multi-variate analysis). said Siddharth Wayangankar, M.D., University of Florida, who presented the study, claims LOS may have immense impact on future care for aortic stenosis patients.

The study also compared one-year outcomes based on LOS. DD post TAVR was significantly associated with higher 1-year all-cause mortality with separation of curves noted immediately post procedure. Even after adjusting for in-hospital complications, DD was an independent predictor of one-year all-cause mortality.

“The predictors from our study could have a huge impact on future clinical care of TAVR patients.” Wayangankar said. “Pre-TAVR, these predictors could be used to develop bedside risk scores for LOS. These could help physicians in patient selection, procedural and post-procedural planning based on patient-specific variables. On a much bigger front, these risk scores could be used by administrators, third-party payors and policy makers for formulating coverage for TAVR procedures and evaluating bundle payments.”

Wayangankar believes the study results have immense post-TAVR implications too. Considering the strong association of DD and outcomes at one year; patients with DD may require a more rigorous follow up schedule to mitigate the higher mortality and hospitalization rates.

The authors note that data from their study (predictors) should be prospectively validated within the TVT registry. Once validated, LOS calculators could help streamline TAVR programs across the world and would help make aortic stenosis care efficient, optimized and sustainable.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

Reference:

1. American Heart Association. Under-recognized heart valve disease kills estimated 25,000 each year. https://news.heart.org/under-recognized-heart-valve-disease-kills-estimated-25000-each-year/. Accessed April 20, 2018.

Related Content

FDA Releases New Report Assessing Quality, Safety and Effectiveness of Medical Device Servicing
News | Cardiovascular Business | June 07, 2018
A new report from the U.S. Food and Drug Administration (FDA) discusses the continued quality, safety and effectiveness...
DAIC Editor Dave Fornell won the 2018 AZBEE national silver award for best blog for "The Future of Cardiology: 17 Technologies to Watch. DAIC magazine - diagnostic and interventional cardiology magazine.
News | Cardiovascular Business | May 14, 2018
May 14, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine was honored with a ...
FDA Announces New Medical Device Safety Action Plan
News | Cardiovascular Business | April 25, 2018
The U.S. Food and Drug Administration (FDA) released a new Medical Device Safety Action Plan outlining how the agency...
DAIC Wins Two 2018 Regional Azbee Awards for Editorial Excellence
Feature | Cardiovascular Business | April 20, 2018
Diagnostic and Interventional Cardiology was honored with a pair of Azbee Awards for editorial excellence at the 2018...
DAIC Editor Dave Fornell displays the 2018 Neal Award for Best Use of Social Media
News | Cardiovascular Business | April 05, 2018
April 5, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine received the 2018 Jesse H.
Veritas Capital Acquiring Three Software Units from GE Healthcare
News | Cardiovascular Business | April 02, 2018
GE Healthcare announced the sale of its Value-Based Care Division — including its software assets for Enterprise...
The annual Azbee Awards are hosted by the American Society of Business Publication Editors (ASBPE) to recognize editorial and design excellence in the business, trade and specialty press. Dave Fornell won blog award for DAIC
News | Cardiovascular Business | March 08, 2018
Scranton Gillette Communications’ Diagnostic and Interventional Cardiology (DAIC) was recently named a 2018
Fysicon announced its acquisition by Canon Medical Systems Corporation.
News | Cardiovascular Business | March 08, 2018
Fysicon announced its acquisition by Canon Medical Systems Corporation. Linda Elberse, CEO of Fysicon, stated: "Being...
ACC 2018 Cardiovascular Summit Teaches Cardiology Best Practices
News | Cardiovascular Business | February 28, 2018
The American College of Cardiology’s Cardiovascular Summit will begin on Thursday, Feb. 22, 2018, bringing together...
FDA Releases Final Rule on Data Acceptance from Medical Device Clinical Investigations
News | Cardiovascular Business | February 21, 2018
The U.S. Food and Drug Administration (FDA) issued the final rule on “Human Subject Protection; Acceptance of Data from...
Overlay Init